Evidence map›Paper›PMID 24366865›Full record

ArticleThe Journal of biological chemistry2014

Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling.

Derek M Shore, Gemma L Baillie, Dow H Hurst, Frank Navas, Herbert H Seltzman, Jahan P Marcu, Mary E Abood, Ruth A Ross, Patricia H Reggio

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 69 citations in OpenAlex.

  1. Negative allosteric modulation of CBNeuropharmacology · 2024
    Article
  2. Should oncologists trust cannabinoids?Frontiers in pharmacology · 2023
    Review
  3. Article
  4. Negative allosteric modulation of CBPharmacological research · 2022
    Article
  5. Review
  6. Review
  7. Review
  8. A Guide to Targeting the Endocannabinoid System in Drug Design.International journal of molecular sciences · 2020
    Review
  9. Article
  10. Review
  11. Article
  12. Structural Insights into CB1 Receptor Biased Signaling.International journal of molecular sciences · 2019
    Review
  13. Article
  14. Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling.Frontiers in molecular neuroscience · 2019
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Derek M ShoreFrom the Center for Drug Discovery, University of North Carolina at Greensboro, Greensboro, North Carolina 27402.
Gemma L Baillie
Dow H Hurst
Frank Navas
Herbert H Seltzman
Jahan P Marcu
Mary E Abood
Ruth A Ross
Patricia H Reggio
University of North Carolina at Greensboro · USRTI International · USTemple University · USUniversity of Aberdeen · GBUniversity of Toronto · CA

Funding

Molecular Determinants of Cannabinoid ActivityR01DA003934 · NIDA · UNIVERSITY OF NORTH CAROLINA GREENSBORO · PI REGGIO, PATRICIA HODAPP · 1985 to 2019
$5.6M
Senior Scientist Award: Molecular Determinants for Cannabinoid ActivityK05DA021358 · NIDA · UNIVERSITY OF NORTH CAROLINA GREENSBORO · PI REGGIO, PATRICIA HODAPP · 2007 to 2016
$1.3M
NIDA NIH HHS K05 DA021358NIDA NIH HHS KO5 DA021358NIDA NIH HHS R01 DA003934
6 · The paper itself

Abstract

The cannabinoid 1 (CB1) allosteric modulator, 5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-piperidin-1-yl-phenyl)-ethyl]-amide) (ORG27569), has the paradoxical effect of increasing the equilibrium binding of [(3)H](-)-3-[2-hydroxyl-4-(1,1-dimethylheptyl)phenyl]-4-[3-hydroxylpropyl]cyclohexan-1-ol (CP55,940, an orthosteric agonist) while at the same time decreasing its efficacy (in G protein-mediated signaling). ORG27569 also decreases basal signaling, acting as an inverse agonist for the G protein-mediated signaling pathway. In ligand displacement assays, ORG27569 can displace the CB1 antagonist/inverse agonist, N-(piperidiny-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide(SR141716A). The goal of this work was to identify the binding site of ORG27569 at CB1. To this end, we used computation, synthesis, mutation, and functional studies to identify the ORG27569-binding site in the CB1 TMH3-6-7 region. This site is consistent with the results of K3.28(192)A, F3.36(200)A, W5.43(279)A, W6.48(356)A, and F3.25(189)A mutation studies, which revealed the ORG27569-binding site overlaps with our previously determined binding site of SR141716A but extends extracellularly. Additionally, we identified a key electrostatic interaction between the ORG27569 piperidine ring nitrogen and K3.28(192) that is important for ORG27569 to act as an inverse agonist. At this allosteric site, ORG27569 promotes an intermediate conformation of the CB1 receptor, explaining ORG27569's ability to increase equilibrium binding of CP55,940. This site also explains ORG27569's ability to antagonize the efficacy of CP55,940 in three complementary ways. 1) ORG27569 sterically blocks movements of the second extracellular loop that have been linked to receptor activation. 2) ORG27569 sterically blocks a key electrostatic interaction between the third extracellular loop residue Lys-373 and D2.63(176). 3) ORG27569 packs against TMH6, sterically hindering movements of this helix that have been shown to be important for receptor activation.

Indexed as

Molecular Dynamics SimulationAllosteric RegulationBinding SitesCannabinoid Receptor AntagonistsHEK293 CellsHumansIndolesPiperidinesProtein BindingPyrazolesReceptor, Cannabinoid, CB1RimonabantSignal Transduction5-chloro-3-ethyl-1H-indole-2-carboxylic acid (2-(4-piperidin-1-yl-phenyl)ethyl)amideCannabinoid Receptor AntagonistsIndolesPiperidinesPyrazolesReceptor, Cannabinoid, CB1RimonabantAllosteric RegulationCannabinoid ReceptorsCannabinoidsG Protein-coupled Receptors (GPCR)Signaling

Identifiers

PMID24366865
PMCPMC3937654
OpenAlexW2006860928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.